Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger

The transaction is expected to result in approximately $175 million to support further development of IMG-007

Merck to acquire HUB Organoids to advance cell culture portfolio

Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development

Edwards’ SAPIEN 3 Ultra RESILIA Valve demonstrates positive outcome

Zydus receives USFDA final approval for Amantadine ER capsules 68.5 mg

Also received tentative approval for 137 mg

Steps taken by India for preparedness against future pandemics

Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting

Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies

Abbott wins CE mark for dual-chamber leadless pacemaker

Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers

AstraZeneca 1Q 2024 revenue up 19% to US$ 12,679 million

Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery

Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024

Growth of Ayush sector is bound to happen: Kotecha

Ayush is expanding beyond wellness to therapeutic wellness